Adalimumab for sight-threatening uveitis in Behçet's disease.
OBJECTIVE
To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy.


METHODS
Case note review. Main outcome measure was recurrence of uveitis.


RESULTS
All patients remained free of recurrence with stable visual acuities.


CONCLUSIONS
Adalimumab appears to maintain disease remission in Behçet's disease.
Mushtaq
B
B
Birmingham and Midland Eye Centre, Birmingham, UK.
Saeed
T
T
Situnayake
R D
RD
Murray
P I
PI
D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001528:Behcet Syndrome / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D012008:Recurrence; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014605:Uveitis / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab